Early decision-making modelling

Models for assessing the economic outcomes of novel technologies have increasingly play a role in the early phases of development. Model contributions to go/no go and priority setting decisions can reveal that further development of a drug is unattractive from an economic viewpoint, or that developing a certain indication is more attractive than another. They may also influence the choice of indication, positioning, or other elements in the continued development of drugs, for instance the design of phase 3 studies. It is argued that high-quality early models form the foundations for future solid evidence on value for money.

IHE has numerous experiences with developing early economic models in various disease areas. As akey example, IHE has developed a model platform that combines both clinical and economic outcomes, and thus is relevant for both clinical researchers and investors.